GeneralConnection.com ➔ Dictionary
Dictionary Search

mrd

Synonyms

Noun

1. machine readable dictionary

2. MRD, electronic dictionary, lexical database

Usage
MRD Test Predicts Chemotherapy Survival Benefit in Colorectal Liver Metastases - CancerNetwork
Natera demonstrates MRD test benefit in colorectal cancer patients - Medical Device Network
Venetoclax-Obinutuzumab Boosts MRD Clearance in CLL - Medscape
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD - AJMC
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma - OncLive
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer - Yahoo Finance
Roll up and show down: MRD’s Hybrid Elite Pickleball Tournament invites everyone to rally - Montrose Daily Press
CEPHEUS Trial and MRD Outcomes in Newly Diagnosed Multiple Myeloma - CancerNetwork
Natera study shows MRD test predicts chemo benefit in liver cancer - Investing.com
Beyond ctDNA: Unlocking Tissue Insights in MRD - Oncodaily
NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care - Targeted Oncology
Natera publishes Signatera survival data in JAMA Oncology - grafa.com
With MRD-Driven Accelerated Approvals, Efficacious Multiple Myeloma Drugs Are Reaching Patients More Quickly and Providing Functional Cures Sooner - ASCO Daily News
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research - Illumina
Quest Diagnostics (DGX) Could Be 4% Undervalued On Haystack MRD Approval - simplywall.st
Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors - OncLive
ctDNA Assay Precise MRD Expands to Breast, Colorectal, Renal Cancer - Targeted Oncology
AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026 - CancerNetwork
MAIA Efficacy and MRD Outcomes in Newly Diagnosed Multiple Myeloma - CancerNetwork
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing - CancerNetwork
How Investors Are Reacting To Quest Diagnostics (DGX) New MRD Test Milestone And Attunio Partnership - simplywall.st
Exclusive | Taylor Swift, Travis Kelce customize car with special license plate at MSG wedding - Page Six
Louise Bach Callesen: Comparing Methylation- and Mutation-Based ddPCR Assays for MRD Detection - Oncodaily
Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care - AJMC
Ultima Genomics releases groundbreaking TRACERx MRD data showing ppmSeq performance and unveils clinical progress of whole genome sequencing at inaugural global MRD Symposium at AACR 2026 - PR Newswire
MRD-Guided CLL Treatment Duration: Personalization or Malpractice? - AJMC
KLN-1010 In Vivo CAR Achieves 100% MRD Negativity in R/R Myeloma - Targeted Oncology
MRD-Based End Point Set to Surge Under FDA Guidance in Multiple Myeloma - OncLive
Dor Abelman, BS, on Multiple Myeloma: cfDNA WGS vs Plasma Proteomics for Minimally Invasive MRD Assessment - The ASCO Post
Minimal Residual Disease Testing in Multiple Myeloma - ASCO Daily News
Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53 -mutated AML/MDS undergoing allogeneic HCT - Nature
In Vivo CAR T-Cell Therapy Drives Responses and MRD Negativity in R/R Myeloma - OncLive
Why MRD Negativity is the Modern Goal in Myeloma Treatment - Cure Today
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials - The ASCO Post
Navigating FDA Expectations for Minimal Residual Disease (MRD) in Multiple Myeloma - Applied Clinical Trials Online
MRD Testing in Blood Cancer: Aiming to Improve Treatment Strategies - AstraZeneca
Allogeneic CAR T Cema-Cel Boosts MRD Clearance in LBCL - Targeted Oncology
From Trial Data to Clinical Practice: DVRd, MRD Testing, and Payer Coverage Considerations in NDMM - AJMC
Azacitidine Triplet Produces Durable MRD-Negative Remissions in IDH1+ AML - CancerNetwork
Is MRD Testing to Guide Cancer Treatment Ready for Prime Time? - ASCO Daily News
Role of ASCT, Transplant, and MRD Are Examined in NDMM - Targeted Oncology
Illumina Announces MRD Kit Ahead of ASCO Meeting - Genetic Engineering and Biotechnology News
MRD End Point Brings “Positive Change” to Multiple Myeloma Research - CancerNetwork
Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study - Nature
The Future of MRD in Breast Cancer Treatment - Targeted Oncology
FDA Approves Adjuvant Atezolizumab for ctDNA MRD–Positive MIBC - Targeted Oncology
MRD Status Determined by ctDNA Identifies Distant Recurrence Risk in TNBC - Targeted Oncology
Navigating FDA Expectations for MRD in Multiple Myeloma - IQVIA
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH - Yahoo Finance
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer - The ASCO Post
FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma - Fierce Biotech
Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence - MedTech Dive
Practical Application of MRD and Fixed-Duration Therapy in Clinical Practice - CancerNetwork
Dose-Adjusted EPOCH Plus Tafasitamab ± Rituximab Yields MRD Negativity in Newly Diagnosed, Ph– B-ALL - OncLive
Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk - PR Newswire
Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort - Nature
Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM - CancerNetwork
MRD as a Development Strategy: The Paradigm Shift Reshaping Oncology Trial Design - Syneos Health
MRD Is Now the Endpoint That Matters: The EMN24 IsKia Trial Just Proved It - The Clinical Trial Vanguard
MRD Negativity Following Liso-Cel Linked to Longer PFS in R/R Follicular Lymphoma - Cancer Therapy Advisor
CAR T Achieves 100% MRD Negativity in Newly Diagnosed Multiple Myeloma - Targeted Oncology
The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma - CancerNetwork
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL - Pharmacy Times – Pharmacy Practice News and Expert Insights
MRD as a Therapeutic Compass: Pharmacists at the Helm of Adaptive Oncology - Pharmacy Times – Pharmacy Practice News and Expert Insights
Time-Limited Zanubrutinib Plus Venetoclax: MRD-Guided Outcomes from SEQUOIA Arm D - CancerNetwork
MRD as a Breakthrough Regulatory End Point in the EXCALIBER-RRMM Trial - Targeted Oncology
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan - Yahoo Finance
Can MRD Testing Enable Treatment Breaks in Metastatic GE Cancer? - Targeted Oncology
Mount Ridley Mines (ASX:MRD) Climbs as Scandium Strategy Moves Forward - Kalkine
Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma - Targeted Oncology
Single-Cell MRD Assessment in AML: Advancing Beyond Standard Care - the-scientist.com
New MRD data may help identify recurrence risk in triple-negative breast cancer - STAT
Foundation Medicine buying Saga Dx and its MRD test for $595M - BioWorld News
Myriad Genetics Expands Availability of Precise MRD™ for - GlobeNewswire
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Yahoo Finance
Noninvasive Blood Test Launched for Myeloma MRD Monitoring - Cure Today
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing - Yahoo Finance
AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma - Oncology Central
Natera Pushes MRD And Panorama Into Treatment Guiding Roles - Yahoo Finance
What MRD Testing Can Mean for Patients With Breast Cancer and Survivors - Cure Today
MRD-Guided Adaptation and the Challenge of Standardizing Response-Based Therapy - OncLive
ctDNA Assays Advance Breast Cancer MRD Detection, Prompt Critical Application Questions - OncLive
Bespoke ctDNA Test Detects MRD in Lung Cancer Patients Years Before Imaging - Inside Precision Medicine
WEBINAR | Executing MRD in Oncology Trials: From Protocol Design to Commercial Impact - Syneos Health
Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout - Medical Device Network
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing - Morningstar
Beyond the Bottleneck: Engineering Sensitive Bespoke MRD Assays - the-scientist.com
FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval - AJMC
ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence - Medical Device Network
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval - Yahoo
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update - Yahoo Finance
Whole-Genome Sequencing-Based MRD Detection Under Study in Resectable Renal Cell Carcinoma - Taigo Kato - UroToday
Tumor-Informed vs Tumor-Agnostic ctDNA: A Deep Dive Into MRD Assay Selection - Targeted Oncology
Off-the-Shelf CAR T Shows 58.3% MRD Clearance in Pretreated LBCL Group - CancerNetwork
CD38 Antibody Exposure vs. Refractoriness and MRD Negativity as Treatment Goal - Targeted Oncology
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma - CancerNetwork
Manale El Kharbili, PhD, on a Novel Strategy to Eliminate MRD in HER2-Mutant NSCLC - The ASCO Post
Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease - PR Newswire
Closing Perspectives: Triplets, Oral Therapy, MRD Evolution, and the Future of AML Care - OncLive
AML MRD: NGS shows gene-specific clearance, undermining binary MRD calls - Vera Health
Foreign Language Equivalents
Foreign Language Equivalents of 'mrd'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
rmd,   mrrd,   mmrd,   mrdd,   nrd,   ,rd,   mdr,   med,   mr,   mrs,   rd,   mrf,   md,   mtd
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z